» Articles » PMID: 12720119

Prognostic Markers and Criteria to Initiate Therapy in Waldenstrom's Macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

Overview
Journal Semin Oncol
Specialty Oncology
Date 2003 Apr 30
PMID 12720119
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

This presentation represents consensus recommendations on prognostic markers and criteria to initiate therapy in patients with Waldenstrom's macroglobulinemia (WM), which were prepared in conjunction with the Second International Workshop held in Athens, Greece during September 2002. The panel recommended that initiation of therapy should not be based on the IgM level per se since this may not correlate with the clinical manifestations of WM. The consensus panel agreed that initiation of therapy was appropriate for patients with constitutional symptoms such as recurrent fever, night sweats, fatigue due to anemia, or weight loss. The presence of progressive, symptomatic lymphadenopathy or splenomegaly provide additional reasons to begin therapy. The presence of anemia with a hemoglobin value of <or= 10 g/dL or a platelet count < 100 x 10(9)/L due to marrow infiltration also justifies treatment. Certain complications such as hyperviscosity syndrome, symptomatic sensorimotor peripheral neuropathy, systemic amyloidosis, renal insufficiency, or symptomatic cryoglobulinemia may also be indications for therapy. Recommendations for follow-up of watch-and-wait patients are that those with monoclonal gammopathy of undetermined significance (MGUS) should have serum protein electrophoresis repeated each year. Patients with asymptomatic (smoldering) macroglobulinemia should be evaluated every 6 months. Regarding prognostic markers, hemoglobin and beta(2)-microglobulin levels at diagnosis are important prognostic markers in WM: they influence the timing of treatment and survival. Age is a consistently important prognostic factor for survival. However, the panel felt that current data are inadequate to support the use of any prognostic marker to select the timing and type of therapy, and called for studies on the application of prognostic markers in WM.

Citing Articles

Tumor-Associated Macrophage (TAM)-Related Cytokines, sCD163, CCL2, and CCL4, as Novel Biomarkers for Overall Survival and Time to Treatment in Waldenstrom's Macroglobulinemia: Emphasis on Asymptomatic WM.

Gkiokas A, Papadatou-Gigante M, Gkioka A, Koudouna A, Tryfou T, Alexandropoulos A Cells. 2025; 14(4).

PMID: 39996747 PMC: 11853255. DOI: 10.3390/cells14040275.


A case of renal infiltration by Bence Jones protein kappa-producing lymphoplasmacytic lymphoma.

Sonomura K, Ehara H, Adachi H, Yamane Y, Kawata E, Mori Y CEN Case Rep. 2025; .

PMID: 39946076 DOI: 10.1007/s13730-025-00977-4.


The landscape of rare genetic variants in familial Waldenström macroglobulinemia.

Pemov A, Kim J, Luo W, Liu J, Graham C, Jones K Blood Neoplasia. 2024; 1(2).

PMID: 39036705 PMC: 11258892. DOI: 10.1016/j.bneo.2024.100013.


Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 1: Epidemiology, Pathogenesis, Clinicopathologic Characteristics, Differential Diagnosis, Risk Stratification, and Clinical Problems.

Bibas M, Sarosiek S, Castillo J Mediterr J Hematol Infect Dis. 2024; 16(1):e2024061.

PMID: 38984103 PMC: 11232678. DOI: 10.4084/MJHID.2024.061.


Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia.

Zanwar S, Le-Rademacher J, Durot E, DSa S, Abeykoon J, Mondello P J Clin Oncol. 2024; 42(21):2527-2536.

PMID: 38788183 PMC: 11268554. DOI: 10.1200/JCO.23.02066.